Back to Feed
总结
诺和诺德在美国推出Wegovy减重药的每日口服版本（先以起始剂量上市），使原本每周注射的GLP-1疗法新增“吃药”选择。多家媒体称该产品已进入药房渠道，被视为扩大用药人群、改善依从性并与同类减重药展开竞争的重要一步。随着口服剂型加入战局，市场预期将加剧医保谈判与企业定价博弈，可能引发更明显的价格战与供给分配调整，并对2026年减重药市场格局产生影响。
正文
Novo Nordisk launches Wegovy weight-loss pill in US, triggering price war The Guardian Starter dose of Wegovy now available as a daily pill instead of weekly injection CNN Novo Nordisk's Wegovy Pill Hits Pharmacies. It's the Latest Move in the Weight-Loss Showdown. Barron's First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. CNBC What to watch for in weight loss drugs in 2026: Price changes, GLP-1 pills and more NBC News
发布时间：